Abstract: A system for manufacturing a three-dimensional dental laminate according to the present invention includes at least one processor and a memory. The memory stores instructions causing the at least one processor to perform in response to execution of the instructions, receiving images including a user's teeth, estimating poses of a camera by analyzing the received images, computing sparse 3D points by tracking feature points in the received images and triangulating a three-dimensional position of the feature points based on relative movements among the estimated poses of the camera, generating a three-dimensional tooth modeling file based on the sparse 3D points and adjusting for the size of an actual tooth, generating a three-dimensional dental laminate modeling file based on the adjusted three-dimensional tooth modeling file, and manufacturing a three-dimensional dental laminate based on the generated three-dimensional dental laminate modeling file.

Abstract: Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.

Abstract: The present invention provides for a method of treatment of IgA nephropathy, which method comprises: (i) identifying a pharmaceutically acceptable composition intended to treat IgA nephropathy comprising budesonide and one or more pharmaceutically-acceptable excipients that provide for a modified release of said budesonide after administration to the gastrointestinal tract, which composition fulfils the following requirements in a standard in vitro USP<711>/Ph.Eur. 2.9.3 dissolution test using a dissolution apparatus according to Apparatus 2 (Paddle Apparatus) of said test; (a) the composition fulfils the requirement that no more than about 10% of the budesonide is released into the dissolution medium within about 120 minutes, when the dissolution medium is aqueous and has a pH of about 1.

Abstract: The present invention relates to a method for preparing a microcapsule and to a method for preparing a microcapsule composition. The present invention also relates to the microcapsule and the microcapsule composition per se. The present invention also relates to uses of the microcapsules and to methods involving the microcapsule, including to prepare a formulated product. The present invention also relates to the formulated product per se.

Abstract: The invention is directed to the field of therapeutic formulations, in particular to lyophilization of a therapeutic cargo molecule, such as RNA. The invention provides a method for lyophilization of a molecule. The present disclosure further describes a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine, a therapeutic and a kit or kit of parts. Moreover, the disclosure herein provides a novel lyophilization excipient that protects the composition from degrading when, for example, lyophilizing RNA. The use of the inventive method further includes the manufacture of a composition that can be used after lyophilization with equivalent therapeutic effect and composition integrity.

Abstract: A sublingual phentermine spray composition for daytime use comprises phentermine in a pharmaceutically-acceptable carrier and a sublingual phentermine spray composition for nighttime use comprises phentermine and a sleep aid in a pharmaceutically-acceptable carrier. Sublingual administration of sublingual phentermine spray compositions in accordance with the present disclosure provides an alternative to oral administration, avoiding such side effects as daytime drowsiness and intestinal disturbances. Nighttime use compositions comprising a sleep aid such as melatonin help manage the usual insomnia experienced when using phentermine. These compositions find use in suppressing appetite, for losing weight, and for maintaining a desired personal appearance.

Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

Abstract: The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive days, wherein a first daily dose of Cebranopadol is administered on every day of the first administration interval; and (ii) a second administration interval, which lasts for at least 2 consecutive days and directly follows the first administration interval without interruption, wherein a second daily dose of Cebranopadol is administered on every day of the second administration interval; wherein the first daily dose of Cebranopadol is lower than the second daily dose of Cebranopadol.

Abstract: Provided is a medicine and a method for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring normal immune state. A medicine for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring a normal immune state, includes, as an active ingredient, a compound selected from the group consisting of: (i) a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein the respective reference numerals are as described in the specification, (ii) a cyclosporine, and (iii) rapamycin or a derivative thereof.

Abstract: Human therapeutic treatment compositions comprising a curcumin component, a harmine component, and an isovanillin component, preferably all three in combination. The agents are synergistically effective for treatment of human conditions, especially human cancers, such as pancreatic cancers.

Abstract: The disclosure provides methods for administering buprenorphine in a healthcare setting by an administering practitioner to a patient in need thereof. The methods of the disclosure comprise obtaining buprenorphine from a REMS-certified pharmacy or a REMS-certified healthcare setting. Said administering does not require the administering practitioner to be REMS-certified.

Abstract: The present invention is directed to compositions containing a fatty acid amide hydrolase inhibitor and methods of use thereof for treatment of trauma-related psychiatric disorders in a patient in need thereof, particularly those that exhibiting hyperarousal symptomatology.

Abstract: Provided in the present invention is a compound acting as a KRAS G12D inhibitor; specifically provided in the present invention is a compound of the structure shown in the following formula (I), or an optical isomer, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative, a hydrate, or a solvate thereof. The present compound can be used for the treatment or prevention of diseases or conditions associated with the activity or expression of KRAS G12D.

Abstract: The present disclosure provides methods for treating hematological malignancies and Ewing's sarcoma using menin inhibitors. Compositions for use in these methods are also provided.

Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

Abstract: The present invention relates to methods for the treatment of cancers, as well as pharmaceutical preparations of compounds useful in such treatments.

Abstract: The present invention provides use of a steroid compound in preparing drugs for preventing and/or treating presbyopia. The steroid compound provided by the present invention is represented by formula (I). The steroid compound has the effect of treating, alleviating and preventing presbyopia, and can greatly alleviate and/or cure presbyopia to improve vision.

Abstract: As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.

Abstract: This application provides an adjustment method, an electronic apparatus, and a communication system, relates to the field of electronic apparatus technologies, and may be applied to a new energy vehicle. The method includes the electronic apparatus receiving a first message that indicates to adjust a temperature of a battery of a vehicle to a target temperature. The method further includes the electronic apparatus adjusting the temperature of the battery of the vehicle based on the first message, to cause the temperature of the battery of the vehicle to be adjusted to the target temperature when the vehicle arrives at a charging station. In this way, the temperature of the battery is adjusted before the vehicle arrives at the charging station, reducing time for adjusting the temperature.

Abstract: An infant car seat includes a seat base and a stability leg. The stability leg includes an upper leg tube, a middle leg tube, a lower leg tube, a rotary member, a first latch and a second latch. The middle leg tube includes at least one hole. The lower leg tube includes at least one opening. The rotary member is assembled with the seat base and affixed to the upper leg tube. The first latch is disposed on a bottom of the upper leg tube and adapted to detachably engage with the at least one hole for constraining a movement between the upper leg tube and the middle leg tube. The second latch is disposed on a bottom of the middle leg tube, and adapted to detachably engage with the at least one opening for constraining a movement between the middle leg tube and the lower leg tube.